Farr Laboratories, LLC – Trademark Portfolio
Entity Type: 16
Farr Laboratories, LLC holds 28 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 26 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include Q-UROL, BP-QMAX, PROUROL, TRIVEREX, and MULTIRIGHT. The owner is based in Los Angeles, CA.
421 North Rodeo Drive, Garden Level
Los Angeles, CA 90210
Showing of trademarks Trademarks
Trademark Classifications
Farr Laboratories, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Farr Laboratories, LLC have?
Farr Laboratories, LLC has 28 U.S. trademarks filed with the USPTO. Of these, 7 registered, 5 abandoned, 16 cancelled.
What trademark classes does Farr Laboratories, LLC file in?
Farr Laboratories, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Farr Laboratories, LLC's most well-known trademarks?
Farr Laboratories, LLC's registered trademark portfolio includes well-known marks such as Q-UROL, BP-QMAX, PROUROL, TRIVEREX, and MULTIRIGHT. These are among 7 currently registered trademarks in the portfolio.
What is Farr Laboratories, LLC's trademark registration success rate?
Farr Laboratories, LLC has a 25% trademark registration rate, with 7 out of 28 resolved applications resulting in successful registration. Currently, 0 applications are pending review.